INTRODUCTION: The urokinase-type plasminogen activator receptor (uPAR) and its ligand (suPAR) are involved in numerous physiological and pathological pathways. Previous studies have shown that an elevated plasma suPAR level is associated with disease severity and mortality. The aim of this prospective observational study was to determine if the suPAR level was associated with readmission and mortality in the acute medical setting. METHODS: Plasma suPAR levels were measured in 1,036 patients at admission. Follow-up ranged 3-10 months. Cox proportional hazards model was used to assess the relative contribution of different risk factors to mortality and readmission. The ANOVA test and Pearson's chi-squared test were used to compare suPAR tertile level with various variables. RESULTS: The highest suPAR tertile level was significantly associated with mortality within 30 days after discharge, with a 6.66 hazard ratio (HR). Similar associations were found with readmission within the maximum observation period (HR = 2.26) and within 30 days (HR = 2.08), although the latter became insignificant when covariates were included. CONCLUSIONS: This study confirms previous findings of increased mortality and adds the finding that increased long-term readmission rates are associated with elevated suPAR levels. The present data do, however, not indicate that suPAR may serve as an independent biomarker for increased risk of short-term readmission in the acute medical setting. FUNDING: This study was funded by a grant from ViroGates A/S, the company that produces the suPARnostic assay. TRIAL REGISTRATION: No: H-B-2009-075.
INTRODUCTION: The urokinase-type plasminogen activator receptor (uPAR) and its ligand (suPAR) are involved in numerous physiological and pathological pathways. Previous studies have shown that an elevated plasma suPAR level is associated with disease severity and mortality. The aim of this prospective observational study was to determine if the suPAR level was associated with readmission and mortality in the acute medical setting. METHODS: Plasma suPAR levels were measured in 1,036 patients at admission. Follow-up ranged 3-10 months. Cox proportional hazards model was used to assess the relative contribution of different risk factors to mortality and readmission. The ANOVA test and Pearson's chi-squared test were used to compare suPAR tertile level with various variables. RESULTS: The highest suPAR tertile level was significantly associated with mortality within 30 days after discharge, with a 6.66 hazard ratio (HR). Similar associations were found with readmission within the maximum observation period (HR = 2.26) and within 30 days (HR = 2.08), although the latter became insignificant when covariates were included. CONCLUSIONS: This study confirms previous findings of increased mortality and adds the finding that increased long-term readmission rates are associated with elevated suPAR levels. The present data do, however, not indicate that suPAR may serve as an independent biomarker for increased risk of short-term readmission in the acute medical setting. FUNDING: This study was funded by a grant from ViroGates A/S, the company that produces the suPARnostic assay. TRIAL REGISTRATION: No: H-B-2009-075.
Authors: Ria M Holstein; Santeri Seppälä; Johanna Kaartinen; Mari Hongisto; Harri Hyppölä; Maaret Castrén Journal: J Clin Med Date: 2022-06-08 Impact factor: 4.964
Authors: Shengyuan Luo; Josef Coresh; Adrienne Tin; Casey M Rebholz; Teresa K Chen; Salim S Hayek; Melissa Tracy; Michael S Lipkowitz; Lawrence J Appel; Andrew S Levey; Lesley A Inker; Jochen Reiser; Morgan Erika Grams Journal: Clin J Am Soc Nephrol Date: 2018-06-14 Impact factor: 8.237
Authors: Andreas Sandø; Martin Schultz; Jesper Eugen-Olsen; Lars Simon Rasmussen; Lars Køber; Erik Kjøller; Birgitte Nybo Jensen; Lisbet Ravn; Theis Lange; Kasper Iversen Journal: Scand J Trauma Resusc Emerg Med Date: 2016-08-05 Impact factor: 2.953
Authors: Martin Schultz; Line Jee Hartmann Rasmussen; Malene H Andersen; Jakob S Stefansson; Alexander C Falkentoft; Morten Alstrup; Andreas Sandø; Sarah L K Holle; Jeppe Meyer; Peter B S Törnkvist; Thomas Høi-Hansen; Erik Kjøller; Birgitte Nybo Jensen; Morten Lind; Lisbet Ravn; Thomas Kallemose; Theis Lange; Lars Køber; Lars Simon Rasmussen; Jesper Eugen-Olsen; Kasper Karmark Iversen Journal: Scand J Trauma Resusc Emerg Med Date: 2018-08-28 Impact factor: 2.953
Authors: Martin Schultz; Line J H Rasmussen; Thomas Høi-Hansen; Erik Kjøller; Birgitte N Jensen; Morten N Lind; Lisbet Ravn; Thomas Kallemose; Theis Lange; Lars Køber; Lars S Rasmussen; Jesper Eugen-Olsen; Kasper K Iversen Journal: Dis Markers Date: 2019-05-19 Impact factor: 3.434
Authors: Martin Schultz; Line Jee Hartmann Rasmussen; Nicolas Carlson; Rasmus Bo Hasselbalch; Birgitte Nybo Jensen; Lotte Usinger; Jesper Eugen-Olsen; Christian Torp-Pedersen; Lars Simon Rasmussen; Kasper Karmark Iversen Journal: BMC Geriatr Date: 2019-05-16 Impact factor: 3.921
Authors: R Rubio Díaz; E de Rafael González; E Martín Torres; E Valera Núñez; A M López Martos; D Melguizo Melguizo; M P Picazo Perea; P J López García; P Fuentes Bullejos; M Chafer Rudilla; J F Carretero Gómez; A Julián-Jiménez Journal: Rev Esp Quimioter Date: 2021-12-03 Impact factor: 1.553
Authors: Line J H Rasmussen; Steen Ladelund; Thomas H Haupt; Gertrude E Ellekilde; Jesper Eugen-Olsen; Ove Andersen Journal: Crit Care Med Date: 2018-12 Impact factor: 7.598